Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACHCNASDAQ:NGNENASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACHCAcadia Healthcare$27.37-3.6%$35.62$26.72▼$82.41$2.54B1.381.42 million shs1.61 million shsNGNENeurogene$8.79-9.1%$16.29$8.50▼$74.49$131.24M1.01213,517 shs336,586 shsTSHATaysha Gene Therapies$1.22-3.2%$1.63$1.17▼$4.32$250.10M0.962.70 million shs1.79 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACHCAcadia Healthcare-3.56%-9.13%-7.78%-38.24%-63.90%NGNENeurogene-9.10%-39.46%-48.02%-62.16%-80.00%TSHATaysha Gene Therapies-3.17%-36.79%-28.24%-36.46%-55.15%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACHCAcadia Healthcare4.6125 of 5 stars4.32.00.05.03.20.02.5NGNENeurogene2.1029 of 5 stars3.61.00.00.02.01.71.3TSHATaysha Gene Therapies1.7882 of 5 stars3.51.00.00.01.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACHCAcadia Healthcare 2.63Moderate Buy$52.1990.67% UpsideNGNENeurogene 3.13Buy$59.80580.32% UpsideTSHATaysha Gene Therapies 3.00Buy$6.63443.03% UpsideCurrent Analyst Ratings BreakdownLatest ACHC, NGNE, and TSHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/25/2025ACHCAcadia HealthcareMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$48.00 ➝ $37.003/25/2025NGNENeurogeneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/25/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $50.003/3/2025ACHCAcadia HealthcareRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$64.00 ➝ $43.003/3/2025ACHCAcadia HealthcareKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$70.00 ➝ $65.002/28/2025ACHCAcadia HealthcareBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $44.502/28/2025ACHCAcadia HealthcareBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$43.00 ➝ $35.002/27/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.002/26/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.001/10/2025ACHCAcadia HealthcareRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$64.00 ➝ $64.001/7/2025ACHCAcadia HealthcareTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$70.00 ➝ $66.00(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACHCAcadia Healthcare$3.15B0.81$3.38 per share8.10$30.17 per share0.91NGNENeurogene$925K141.88N/AN/A$14.51 per share0.61TSHATaysha Gene Therapies$8.33M30.01N/AN/A$0.40 per share3.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACHCAcadia Healthcare-$21.67M$2.778.978.071.468.99%11.12%5.77%4/29/2025 (Estimated)NGNENeurogene-$36.32M-$4.27N/AN/AN/AN/A-32.81%-27.96%5/9/2025 (Estimated)TSHATaysha Gene Therapies-$111.57M-$0.361.94N/AN/A-229.67%-106.36%-49.16%5/13/2025 (Estimated)Latest ACHC, NGNE, and TSHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/24/2025Q4 2024NGNENeurogene-$1.04-$0.99+$0.05-$0.99N/A$0.93 million2/26/2025Q4 2024TSHATaysha Gene Therapies-$0.08-$0.07+$0.01-$0.07$2.05 million$2.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACHCAcadia HealthcareN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACHCAcadia Healthcare0.601.071.07NGNENeurogeneN/A9.099.09TSHATaysha Gene Therapies0.485.515.51Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACHCAcadia HealthcareN/ANGNENeurogene52.37%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipACHCAcadia Healthcare2.00%NGNENeurogene9.92%TSHATaysha Gene Therapies2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACHCAcadia Healthcare23,50092.91 million91.03 millionOptionableNGNENeurogene9014.93 million13.38 millionOptionableTSHATaysha Gene Therapies180205.00 million199.41 millionOptionableACHC, NGNE, and TSHA HeadlinesRecent News About These CompaniesTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 4 at 8:00 AM | globenewswire.comWhy Taysha Gene Therapies, Inc.’s (TSHA) Stock Is Down 11.15%April 1, 2025 | aaii.comIs Taysha Gene Therapies (TSHA) the Best Short Squeeze Stock to Buy According to Analysts?March 19, 2025 | msn.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from AnalystsMarch 11, 2025 | marketbeat.comTaysha Gene Therapies (TSHA) to Release Earnings on TuesdayMarch 11, 2025 | marketbeat.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 7, 2025 | globenewswire.comTruist Financial Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)February 28, 2025 | markets.businessinsider.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | msn.comQ4 2024 Taysha Gene Therapies Inc Earnings CallFebruary 27, 2025 | finance.yahoo.comTaysha Gene Therapies Reports 2024 Financial ResultsFebruary 27, 2025 | tipranks.comTaysha Gene Therapies reports FY24 EPS (36c) vs (96c) last yearFebruary 26, 2025 | markets.businessinsider.comTaysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue EstimatesFebruary 26, 2025 | zacks.comTaysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate UpdateFebruary 26, 2025 | globenewswire.comTaysha Gene Therapies Inc (TSHA) Q4 2024: Everything You Need To Know Ahead Of EarningsFebruary 25, 2025 | finance.yahoo.comTaysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26February 19, 2025 | globenewswire.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comTaysha Gene Therapies Is Showing Promise For Rett SyndromeJanuary 27, 2025 | seekingalpha.comWhy Taysha Gene Therapies Inc (TSHA) Stock is Currently -11.97% Off from Its 20-Day SMA?January 24, 2025 | bovnews.comTaysha Gene Therapies announces inducement grant under Nasdaq listing ruleJanuary 3, 2025 | markets.businessinsider.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)January 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACHC, NGNE, and TSHA Company DescriptionsAcadia Healthcare NASDAQ:ACHC$27.37 -1.01 (-3.56%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$26.54 -0.83 (-3.05%) As of 04/4/2025 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.Neurogene NASDAQ:NGNE$8.79 -0.88 (-9.10%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$9.19 +0.40 (+4.55%) As of 04/4/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Taysha Gene Therapies NASDAQ:TSHA$1.22 -0.04 (-3.17%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$1.22 0.00 (0.00%) As of 04/4/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/31 - 04/04 Conagra Stock Could Thrive as Tariffs Hit Other Sectors Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
